BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ansari M, Huezo-Diaz P, Rezgui MA, Marktel S, Duval M, Bittencourt H, Cappelli B, Krajinovic M. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. Bone Marrow Transplant 2016;51:377-83. [PMID: 26691424 DOI: 10.1038/bmt.2015.321] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang C, Qu Y, Liu S, Nie S, Jiang H. Hematopoietic stem cell transplantation for thalassemia major using HLA fully-matched and mismatched donor grafts. Transl Pediatr 2021;10:1552-65. [PMID: 34295770 DOI: 10.21037/tp-20-415] [Reference Citation Analysis]
2 Waespe N, Strebel S, Jurkovic Mlakar S, Krajinovic M, Kuehni CE, Nava T, Ansari M. Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review. J Pers Med 2021;11:347. [PMID: 33925809 DOI: 10.3390/jpm11050347] [Reference Citation Analysis]
3 Sun Y, Huang J, Hao C, Li Z, Liang W, Zhang W, Chen B, Yang W, Hu J. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. Cancer Chemother Pharmacol 2020;85:293-308. [PMID: 31834435 DOI: 10.1007/s00280-019-04001-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Robin S, Hassine KB, Muthukumaran J, Jurkovic Mlakar S, Krajinovic M, Nava T, Uppugunduri CRS, Ansari M. A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation. BMC Mol and Cell Biol 2022;23. [DOI: 10.1186/s12860-021-00402-5] [Reference Citation Analysis]
5 Pita-Oliveira M, Rodrigues-Soares F. Influence of GSTM1, GSTT1, and GSTP1 genetic polymorphisms on disorders in transplant patients: a systematic review. Drug Metab Pers Ther 2021. [PMID: 34856092 DOI: 10.1515/dmpt-2021-0165] [Reference Citation Analysis]
6 Willcox A, Wong E, Nath C, Janson B, Harrison SJ, Hoyt R, Bajel A, Shaw P, Ritchie D, Grigg A. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. Ann Hematol 2018;97:2509-18. [DOI: 10.1007/s00277-018-3447-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L, Théoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, Bittencourt H, Krajinovic M. GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget 2017;8:90852-67. [PMID: 29207608 DOI: 10.18632/oncotarget.20310] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
8 Deng L, Lu Y, Yang D, Yang F, Ruan H, Wei C, Lai K, Pang L. Placental transcriptome sequencing combined with bioinformatics predicts potential genes and circular RNAs associated with hemoglobin Bart's hydrops fetalis syndrome. J Obstet Gynaecol Res 2021. [PMID: 34935248 DOI: 10.1111/jog.15126] [Reference Citation Analysis]
9 Kim B, Lee JW, Hong KT, Yu KS, Jang IJ, Park KD, Shin HY, Ahn HS, Cho JY, Kang HJ. Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients. Sci Rep 2017;7:1711. [PMID: 28490733 DOI: 10.1038/s41598-017-01861-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
10 Remy A, Théorêt Y, Ansari M, Bittencourt H, Ducruet T, Nava T, Pastore Y, Rezgui MA, Krajinovic M, Kleiber N. Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls. J Pediatr Hematol Oncol 2021;43:e867-72. [PMID: 33661168 DOI: 10.1097/MPH.0000000000002106] [Reference Citation Analysis]
11 Kim MG, Kwak A, Choi B, Ji E, Oh JM, Kim K. Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis. Basic Clin Pharmacol Toxicol 2019;124:691-703. [PMID: 30511436 DOI: 10.1111/bcpt.13185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Nava T, Rezgui MA, Uppugunduri CRS, Curtis PH, Théoret Y, Duval M, Daudt LE, Ansari M, Krajinovic M, Bittencourt H. GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2017;23:1918-24. [PMID: 28807770 DOI: 10.1016/j.bbmt.2017.07.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Ben Hassine K, Powys M, Svec P, Pozdechova M, Versluys B, Ansari M, Shaw PJ. Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia. Front Pediatr 2021;9:775485. [PMID: 34956984 DOI: 10.3389/fped.2021.775485] [Reference Citation Analysis]
14 Mlakar V, Curtis PH, Armengol M, Ythier V, Dupanloup I, Hassine KB, Lesne L, Murr R, Mlakar SJ, Nava T, Ansari M. The analysis of GSTA1 promoter genetic and functional diversity of human populations. Sci Rep 2021;11:5038. [PMID: 33658540 DOI: 10.1038/s41598-021-83996-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Alsultan A, Albassam AA, Alturki A, Alsultan A, Essa M, Almuzzaini B, Alfadhel S. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation. Int J Clin Pharm 2020;42:703-12. [PMID: 32140913 DOI: 10.1007/s11096-020-00989-3] [Reference Citation Analysis]
16 Takachi T, Arakawa Y, Nakamura H, Watanabe T, Aoki Y, Ohshima J, Takahashi Y, Hirayama M, Miyamura T, Sugita K, Koh K, Horibe K, Ishii E, Mizutani S, Tomizawa D. Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia. Int J Hematol 2019;110:355-63. [PMID: 31201644 DOI: 10.1007/s12185-019-02684-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Park H, Byun JM, Koh Y, Yoon SS, Park H, Lee J, Shin SJ, Youk J. Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation-Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study. Clin Lymphoma Myeloma Leuk 2019;19:e605-15. [PMID: 31543371 DOI: 10.1016/j.clml.2019.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bradford KL, Liu S, Krajinovic M, Ansari M, Garabedian E, Tse J, Wang X, Shaw KL, Gaspar HB, Candotti F, Kohn DB. Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy. Biol Blood Marrow Transplant 2020;26:1819-27. [PMID: 32653625 DOI: 10.1016/j.bbmt.2020.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]